Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Highlight selection
Radiochemistry
Radiopharmacy
Journal
EJNMMI radiopharmacy and chemistry
ISSN: 2365-421X
Titre abrégé: EJNMMI Radiopharm Chem
Pays: England
ID NLM: 101714628
Informations de publication
Date de publication:
08 Sep 2021
08 Sep 2021
Historique:
received:
12
08
2021
accepted:
27
08
2021
entrez:
8
9
2021
pubmed:
9
9
2021
medline:
9
9
2021
Statut:
epublish
Résumé
The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. This commentary of highlights has resulted in 21 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. Also the first contribution in relation to MRI-agents is included. Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.
Sections du résumé
BACKGROUND
BACKGROUND
The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development.
RESULTS
RESULTS
This commentary of highlights has resulted in 21 different topics selected by each member of the Editorial Board addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals. Also the first contribution in relation to MRI-agents is included.
CONCLUSIONS
CONCLUSIONS
Trends in (radio)chemistry and radiopharmacy are highlighted demonstrating the progress in the research field being the scope of EJNMMI Radiopharmacy and Chemistry.
Identifiants
pubmed: 34495412
doi: 10.1186/s41181-021-00146-9
pii: 10.1186/s41181-021-00146-9
pmc: PMC8426445
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
31Subventions
Organisme : Medical Research Council
ID : MR/P018661/1
Pays : United Kingdom
Informations de copyright
© 2021. The Author(s).
Références
Clin Cancer Res. 2021 Jan 15;27(2):532-541
pubmed: 32958698
Nucl Med Biol. 2021 Jul-Aug;98-99:30-39
pubmed: 34020337
Sci Rep. 2019 Oct 16;9(1):14835
pubmed: 31619702
Nucl Med Biol. 2019 Jul - Aug;74-75:49-55
pubmed: 31085059
EJNMMI Radiopharm Chem. 2021 Jan 7;6(1):1
pubmed: 33411034
EJNMMI Radiopharm Chem. 2021 Feb 12;6(1):8
pubmed: 33580358
Chem Commun (Camb). 2021 May 27;57(43):5286-5289
pubmed: 33942818
Science. 2012 Dec 7;338(6112):1324-7
pubmed: 23224551
J Nucl Med. 2021 Jan;62(1):92-98
pubmed: 32646878
Appl Radiat Isot. 2020 Feb;156:109014
pubmed: 32056692
Cancers (Basel). 2020 May 26;12(6):
pubmed: 32466595
Clin Cancer Res. 2021 Mar 15;27(6):1585-1594
pubmed: 33082213
EJNMMI Radiopharm Chem. 2020 Nov 12;5(1):25
pubmed: 33180205
Angew Chem Int Ed Engl. 2021 Apr 6;60(15):8220-8226
pubmed: 33606332
J Nucl Med. 2020 Apr;61(4):563-569
pubmed: 31586001
Angew Chem Int Ed Engl. 2020 Apr 27;59(18):7256-7260
pubmed: 31995256
Chemistry. 2021 Jul 16;27(40):10369-10376
pubmed: 33890705
EJNMMI Radiopharm Chem. 2021 May 25;6(1):19
pubmed: 34036449
EJNMMI Radiopharm Chem. 2021 Feb 1;6(1):6
pubmed: 33527221
EJNMMI Radiopharm Chem. 2020 May 14;5(1):12
pubmed: 32410136
EJNMMI Radiopharm Chem. 2021 Apr 16;6(1):16
pubmed: 33864154
J Nucl Med. 2021 Feb;62(2):201-207
pubmed: 32591493
J Clin Invest. 2018 May 1;128(5):2116-2126
pubmed: 29509546
EJNMMI Res. 2018 Oct 23;8(1):95
pubmed: 30353250
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):31-37
pubmed: 28891033
EJNMMI Radiopharm Chem. 2021 Feb 26;6(1):10
pubmed: 33638060
Science. 2011 Jan 28;331(6016):445-8
pubmed: 21273483
EJNMMI Radiopharm Chem. 2020 Dec 17;5(1):31
pubmed: 33331982
EJNMMI Radiopharm Chem. 2019 Jul 25;4(1):16
pubmed: 31659499
Cancer. 2019 Aug 1;125(15):2561-2569
pubmed: 31012963
Nucl Med Biol. 2021 Jul-Aug;98-99:40-58
pubmed: 34029984
Clin Cancer Res. 2020 Jul 1;26(13):3110-3116
pubmed: 32245901
EJNMMI Radiopharm Chem. 2020 Nov 9;5(1):22
pubmed: 33169241
EJNMMI Radiopharm Chem. 2021 Mar 24;6(1):14
pubmed: 33761040
Cancer Biother Radiopharm. 2020 Aug;35(6):425-436
pubmed: 32077749
Bioconjug Chem. 2021 Mar 17;32(3):430-447
pubmed: 33630583
Annu Rev Pharmacol Toxicol. 2011;51:45-73
pubmed: 20854171
EJNMMI Radiopharm Chem. 2021 Apr 1;6(1):15
pubmed: 33796967
J Nucl Med. 2017 Jul;58(7):1025-1030
pubmed: 28473593
Eur J Nucl Med Mol Imaging. 2021 Oct;48(11):3618-3630
pubmed: 33954826